Kathy S. Albain mainly investigates Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy. All of her Internal medicine and Lung cancer, Cancer, Randomized controlled trial, Performance status and Clinical endpoint investigations are sub-components of the entire Internal medicine study. Her Oncology research includes themes of Metastatic breast cancer, Proportional hazards model, Hazard ratio and Chemoradiotherapy, Radiation therapy.
Her Breast cancer research is multidisciplinary, relying on both Biomarker, Gynecology and Adjuvant therapy. The concepts of her Surgery study are interwoven with issues in Placebo, Metastasis, Trastuzumab and Intensive care medicine. Her Chemotherapy research incorporates elements of Bone pain, Bisphosphonate and Osteolysis.
Kathy S. Albain focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer. Her research ties Surgery and Internal medicine together. Her study on Oncology also encompasses disciplines like
Her Breast cancer research focuses on subjects like Hazard ratio, which are linked to Proportional hazards model. Her research integrates issues of Taxane and Anthracycline in her study of Chemotherapy. Her biological study deals with issues like Cancer research, which deal with fields such as Notch signaling pathway.
Her primary areas of study are Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer. The Internal medicine study which covers MEDLINE that intersects with Cooperative group and Anastrozole. The various areas that Kathy S. Albain examines in her Breast cancer study include Hazard ratio, Clinical trial, Proportional hazards model and Chemotherapy regimen.
Her Oncology study combines topics in areas such as Adjuvant chemotherapy, MammaPrint, Clinical endpoint and Trastuzumab. She has included themes like Receptor, Tamoxifen, Adverse effect and Hormone receptor in her Chemotherapy study. Her Cancer study integrates concerns from other disciplines, such as High risk patients and Therapeutic regimen.
Her scientific interests lie mostly in Internal medicine, Breast cancer, Oncology, Chemotherapy and Randomized controlled trial. Her studies in Breast cancer integrate themes in fields like Hazard ratio, Prospective cohort study, Chemotherapy regimen and Clinical trial. Her studies deal with areas such as Physical fitness, Cancer, Adjuvant therapy, Confidence interval and Tamoxifen as well as Prospective cohort study.
Her Oncology research integrates issues from Taxane, Clinical endpoint and Docetaxel. Her Chemotherapy research is multidisciplinary, incorporating perspectives in Adjuvant, Receptor, Disease and Anthracycline. The various areas that Kathy S. Albain examines in her Randomized controlled trial study include Progression-free survival, Proportional hazards model and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris;Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
Laura F. Hutchins;Joseph M. Unger;John J. Crowley;Charles A. Coltman.
The New England Journal of Medicine (1999)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi.
Lancet Oncology (2010)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi.
The Lancet (2009)
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow.
Journal of Clinical Oncology (2003)
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice.
Journal of Clinical Oncology (1995)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
Kathy S. Albain;John J. Crowley;Michael LeBlanc;Robert B. Livingston.
Journal of Clinical Oncology (1991)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: